GLP-1 & Dual Agonist Escalation Protocol Guide

Glucagon-like peptide-1 (GLP-1) receptor agonists and multi-target metabolic peptides require strict 4-week step-up escalation paradigms to minimize gastrointestinal intolerance and maximize physiological receptor acclamation.

1. Why Dose Escalation is Essential

When initiating GLP-1 research, receptor sensitivity in the brainstem, vagus nerve, and stomach is high. Rapid dose increases induce significant nausea, delayed gastric emptying discomfort, and early trial dropout.

2. Standard 4-Week Step-Up Schedules

Semaglutide Ramp Schedule:

• Weeks 1–4: 0.25 mg once weekly (Initiation)
• Weeks 5–8: 0.50 mg once weekly (First Step-Up)
• Weeks 9–12: 1.00 mg once weekly (Mid Dose)
• Weeks 13–16: 1.70 mg once weekly (High Intermediate)
• Weeks 17+: 2.40 mg once weekly (Maximum Target)

Tirzepatide (GIP/GLP-1) Ramp Schedule:

• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5.0 mg once weekly
• Weeks 9–12: 7.5 mg once weekly
• Weeks 13–16: 10.0 mg once weekly
• Weeks 17–20: 12.5 mg once weekly
• Weeks 21+: 15.0 mg once weekly

3. Managing Half-Lives & Injection Timing

Semaglutide exhibits an elimination half-life of approximately 7 days (165 hours), whereas Tirzepatide exhibits a half-life of 5 days (120 hours). Because steady-state plasma concentrations take approximately 4 to 5 half-lives to achieve, maintaining consistent weekly dosing interval days is critical for steady receptor activation.